IL1B and neoplasm: The presence of IL-1β in the tumor microenvironment promotes the development of aggressive RCC by inducing the expression of matrix metalloproteinase (MMP) 1, MMP3, MMP10 and MT1-MMP via activation of the transcription factor CCAAT enhancer binding protein β (CEBPβ) [7].